Company
Pfizer
Pfizer has 98 drugs tracked on RxWires: 9 post-market, 8 approved, 31 in Phase 3, 2 in Phase 2/3, 11 in Phase 2, 3 in Phase 1/2, 34 in Phase 1.
- Ticker
- PFE
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Celecoxib | Post-Market | Osteoarthritis, Knee |
| Varenicline Tartrate | Post-Market | Smoking Cessation |
| Gabapentin | Post-Market | Renal Impairment |
| ziprazidone | Post-Market | Schizophrenia |
| ziprasidone | Post-Market | Schizophrenia |
| TIVDAK | Post-Market | Cervical Cancer |
| Dextromethorphan | Post-Market | Common Cold |
| Dexmedetomidine | Post-Market | Heart Disease |
| pregabalin | Post-Market | Fibromyalgia |
| ZITHROMAX | Approved | |
| COLESTID | Approved | |
| STERANE | Approved | |
| VIBRAMYCIN | Approved | |
| UNASYN | Approved | |
| HUMATIN | Approved | |
| DAYPRO ALTA | Approved | |
| ELREXFIO | Approved | |
| Encorafenib | Phase 3 | Neoplasms |
| iv sildenafil | Phase 3 | Pulmonary Hypertension, Familial Persistent, of the Newborn |
| marstacimab | Phase 3 | Hemophilia A or B |
| Enzalutamide | Phase 3 | Hormone Sensitive Prostate Cancer |
| Berobenatide | Phase 3 | Obesity |
| RSVpreF | Phase 3 | Respiratory Syncytial Virus (RSV) |
| Ritlecitinib higher dose | Phase 3 | Severe Alopecia Areata |
| Tilrekimig | Phase 3 | Atopic Dermatitis |
| PG4 | Phase 3 | Pneumococcal Disease |
| Etrasimod | Phase 3 | Ulcerative Colitis |
| Talazoparib with enzalutamide | Phase 3 | mCRPC |
| Abrocitinib | Phase 3 | Atopic Dermatitis |
| 13-valent Pneumococcal Conjugate Vaccine | Phase 3 | Vaccines, Pneumococcal |
| valdecoxib | Phase 3 | Pharyngitis |
| talazoparib plus enzalutamide | Phase 3 | Prostate Cancer |
| Vepdegestrant (ARV-471/PF-07850327) | Phase 3 | Breast Cancer |
| recombinant human growth hormone | Phase 3 | Abdominal Obesity |
| Anidulafungin/Fluconazole | Phase 3 | Candidemia |
| tisotumab vedotin | Phase 3 | Cervical Cancer |
| PF-07248144 | Phase 3 | Breast Cancer |
| Rimegepant | Phase 3 | Migraine |
| Clozapine | Phase 3 | Schizophrenia |
| PF-05280586 | Phase 3 | Follicular Lymphoma |
| tucatinib | Phase 3 | Colorectal Neoplasms |
| ARV-471 | Phase 3 | Advanced Breast Cancer |
| Placebo | Phase 3 | Pain, Perioperative |
| latanoprost 0.005% | Phase 3 | Ocular Hypertension |
| Inotuzumab ozogamicin | Phase 3 | Lymphoma, Non-Hodgkin |
| tolterodine extended release capsule | Phase 3 | Urinary Incontinence |
| Atirmociclib | Phase 3 | Early Breast Cancer |
| Epoetin Hospira | Phase 3 | Chronic Renal Failure Requiring Hemodialysis |
| Sirolimus | Phase 2/3 | Sturge-Weber Syndrome |
| Eplerenone | Phase 2/3 | Breast Cancer |
| PF-07275315 | Phase 2 | Asthma |
| PF-08653945 | Phase 2 | Overweight |
| Voxelotor | Phase 2 | Sickle Cell Disease |
| Clostridium difficile vaccine | Phase 2 | Clostridium Difficile Associated Disease |
| disitamab vedotin | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| PD-0325901 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| UK-453,061 | Phase 2 | HIV-1 |
| PF-08634404 | Phase 2 | Carcinoma |
| Bupivacaine TTS (Bupivacaine Patch) | Phase 2 | Chronic Low Back Pain |
| PF-07220060 | Phase 2 | Liposarcoma |
| Ritlecitinib | Phase 2 | Hidradenitis Suppurativa |
| Multivalent Pneumococcal Vaccine - Formulation 1 | Phase 1/2 | Pneumococcal Disease |
| PF-3512676 | Phase 1/2 | Lymphoma, T-Cell, Cutaneous |
| PF-08154225 | Phase 1/2 | Systemic Lupus Erythematosus |
| SAM-531 | Phase 1 | Alzheimer Disease |
| PF-08046044/SGN-35C | Phase 1 | Hodgkin Disease |
| PF-08046050 | Phase 1 | Colorectal Neoplasms |
| PF-08653944 | Phase 1 | Overweight |
| PF-08052667 | Phase 1 | Non-muscle Invasive Bladder Cancer |
| Amlodipine - reference | Phase 1 | Healthy Volunteers |
| LXR-623 | Phase 1 | Healthy |
| Sinsunatovir | Phase 1 | Healthy |
| Epanutin Infatabs (Phenytoin) | Phase 1 | Healthy |
| sigvotatug vedotin | Phase 1 | Carcinoma, Non-Small Cell Lung |
| PF-07264660 | Phase 1 | Healthy |
| PF-03084014 | Phase 1 | Breast Cancer Metastatic |
| Ibuzatrelvir | Phase 1 | Healthy Participant |
| Encorafenib capsule formulation (CAP) | Phase 1 | Healthy |
| single dose of vepdegestrant as tablet formulation (Treatment A) | Phase 1 | Healthy |
| Treatment A | Phase 1 | Rheumatoid Arthritis |
| PF-02341066 | Phase 1 | Healthy |
| sildenafil citrate 100 mg CT | Phase 1 | Erectile Dysfunction |
| PF-06650833 | Phase 1 | Healthy |
| CAZ-AVI | Phase 1 | Healthy |
| Midazolam | Phase 1 | Healthy Participants |
| Pregabalin controlled release, 82.5 mg | Phase 1 | Healthy |
| Fluticasone Propionate | Phase 1 | Pulmonary Disease, Chronic Obstructive |
| [phenyl-14C]ARV-471 | Phase 1 | Healthy |
| bapineuzumab | Phase 1 | Alzheimer Disease |
| temsirolimus | Phase 1 | Endometrial Cancer |
| PF-06936308 | Phase 1 | Non-Small Cell Lung Cancer |
| Revatio | Phase 1 | Healthy |
| PF-04427429 | Phase 1 | Healthy Volunteers |
| Axitinib 5 MG | Phase 1 | Colorectal Neoplasms Malignant |
| Desvenlafaxine Sustained Release (DVS SR) | Phase 1 | Depressive Disorder, Major |
| HSD-016 | Phase 1 | Healthy Subjects |
| CAZ104 | Phase 1 | Healthy |
| PF-07054894 | Phase 1 | Ulcerative Colitis |
Latest
- Ritlecitinib moved to Phase 2
- pfizer filed 8-K
- pfizer filed 8-K
- Label updated: AZITHROMYCIN DIHYDRATE
- pfizer filed 8-K
Follow Pfizer on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.